Carvedilol, a new antioxidative -blocker, blocks in vitro human peripheral blood T cell activation by downregulating NF-B activity

Authors: Yang S.P.; Ho L.J.; Lin Y.L.; Cheng S.M.; Tsao T.P.; Chang D.M.; Hsu Y.L.; Shih C.Y.; Juan T.Y.; Lai J.H.¹

Source: Cardiovascular Research, Volume 59, Number 3, 1 September 2003 , pp. 776-787(12)

Publisher: Elsevier

Keywords: Carvedilol; Atherosclerosis; T cells; Cytokines; NF- kappa B

Language: English

Document Type: Research article

DOI: 10.1016/S0008-6363(03)00459-0

Affiliations: 1: Rheumatology/Immunology and Allergy, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, No. 325, Sec. 2, Cheng-Kung Rd., Neihu 114, , Taipei, Taiwan, ROC

Links for this article

http://www.ingentaconnect.com/els/00086363/2003/00000059/00000003/art00459
http://openurl.ingenta.com/content?genre=article&issn=0008-6363&volume=59&issue=3&spage=776&epage=787
http://dx.doi.org/10.1016/S0008-6363(03)00459-0